Sponsor

Institut de Recherches Internationales Servier

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Institut de Recherches Internationales Servier appears in 23 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials23
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

23 shown
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesNCT05786924 · lead sponsor · 2023-04-18
RECRUITING
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and DyslipidemiaNCT04591808 · lead sponsor · 2021-09-09
TERMINATED
Efficacy and Safety of S95011 in Primary Sjögren's Syndrome PatientsNCT04605978 · lead sponsor · 2021-08-03
COMPLETED
Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in HypertensionNCT05820880 · lead sponsor · 2019-05-06
COMPLETED
S 81694 Plus Paclitaxel in Metastatic Breast CancerNCT03411161 · lead sponsor · 2018-01-04
COMPLETED
Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes MellitusNCT04744636 · lead sponsor · 2017-04-03
COMPLETED
Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant TreatmentNCT02805439 · lead sponsor · 2016-03-01
COMPLETED
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive SymptomsNCT02626572 · lead sponsor · 2015-02-01
COMPLETED
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast CancerNCT02053636 · lead sponsor · 2013-12-01
COMPLETED
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart FailureNCT02446990 · lead sponsor · 2009-09-01
COMPLETED
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre StudyNCT02441218 · lead sponsor · 2006-09-01
COMPLETED
Efficacy and Safety of Ivabradine in Severe Congestive Heart FailureNCT00202579 · lead sponsor · 2004-09-01
COMPLETED
S90652 in Paediatric HypertensionNCT00202592 · lead sponsor · 2003-11-01
COMPLETED
S90652 in Paediatric HypertensionNCT00202553 · lead sponsor · 2003-07-01
COMPLETED
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)NCT06162572 · collaborator · 2024-08-07
ACTIVE_NOT_RECRUITING
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPNCT06188702 · collaborator · 2024-04-29
ACTIVE_NOT_RECRUITING
PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF StudyNCT04189029 · collaborator · 2019-12-09
UNKNOWN
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple SclerosisNCT03239860 · collaborator · 2017-06-06
TERMINATED
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MSNCT02782858 · collaborator · 2016-04-01
COMPLETED
Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal MuscleNCT01956721 · collaborator · 2013-09-18
TERMINATED
Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal MuscleNCT01014611 · collaborator · 2010-04-01
TERMINATED
Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 DiabetesNCT00145925 · collaborator · 2001-06-01
COMPLETED
The Hypertension in the Very Elderly Trial (HYVET)NCT00122811 · collaborator · 2000-11-01
UNKNOWN

Drugs studied in this sponsor's trials

10 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Institut de Recherches Internationales Servier as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo5
ivabradine3
perindopril3
atorvastatin1
cemiplimab1
cetuximab1
gemcitabine1
paclitaxel1
placebo RxCUI 8375 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 5 trials ivabradine RxCUI 1649480 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials perindopril RxCUI 54552 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials atorvastatin RxCUI 83367 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cemiplimab RxCUI 2058826 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cetuximab RxCUI 318341 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial panitumumab RxCUI 263034 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial

Sponsor roles

lead sponsor14
collaborator9
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.